ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston MA — a merit-award winner at the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO) 2013 Genitourinary Cancers Symposium. Treatment with surgery or radiotherapy, he noted, adds toxicity with the potential to do harm without bringing any additional mortality benefit, for the majority of these patients.
You may also like...
Audio Journal of Oncology 14.2, March 2006 11 Jan, 2006 Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia 9 Apr, 2013 Malaria: one baby in three protected 12 months after vaccination 21 Nov, 2012 Big steps forward for advanced melanoma treatment 10 Oct, 2013
- Previous story Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer
- Next story Low risk localized prostate cancer: no harm from waiting!
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014